Cassava Sciences Inc (SAVA NASDAQ) stock market data APIs
$2.6158
-0.19(-6.8%)
as of March 14, 2025
Cassava Sciences Inc Financial Data Overview
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Prev. Close
2.8105
Open
2.6158
High
2.7993
Low
2.6158
52 wk Range
2.23-42.2
Market Cap
135 M
Shares Outstanding
48 308 K
EPS
-0.57
Beta
-1.24
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Cassava Sciences Inc data using free add-ons & libraries
Get Cassava Sciences Inc Fundamental Data
Cassava Sciences Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -140 314 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-26
- EPS/Forecast: -0.68
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Cassava Sciences Inc News
New
Cassava Sciences Reports 2024 Financial Results and Provides Business Update
Top-line data for REFOCUS-ALZ, the second Phase 3 study of simufilam in Alzheimer’s disease, expected late first-quarter/early second-quarter 2025License agreement brings potential in a new therapeu...
Cassava Sciences Reports 2024 Financial Results and Provides Business Update
Cassava Sciences, Inc. Top-line data for REFOCUS-ALZ, the second Phase 3 study of simufilam in Alzheimer’s disease, expected late first-quarter/early second-quarter 2025 License agreement brings po...
Cassava Sciences Licenses Simufilam Method of Treatment Patent
Cassava Sciences, Inc. Cassava enters into a license agreement with Yale University granting intellectual property rights, including rights to an issued US method of treatment patent for potential tr...
Cassava Sciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – SAVA
NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
